How Good do Current LHRH Agonists Control Testosterone? Can this be Improved with Eligard®?
Authors:
- Bertrand TombalBTBertrand Tombal
- Richard BergesRBRichard Berges
- 1 November 2005
- journal article
- Published by Elsevier in European Urology Supplements
- Vol. 4 (8) , 30-36
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- 218 Failure of luteinizing hormone releasing hormone agonist therapy to achieve castration. Does it exist?European Urology Supplements, 2004
- A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancerExpert Opinion on Pharmacotherapy, 2004
- Luteinising hormone releasing hormone analogues in the treatment of prostate cancerExpert Opinion on Pharmacotherapy, 2002
- Serum Testosterone Suppression and Potential for Agonistic Stimulation During Chronic Treatment With Monthly and 3-month Depot Formulations of Leuprolide Acetate for Advanced Prostate CancerJournal of Urology, 2002
- A Clinical Study Of 22.5 mg. La-2550: A New Subcutaneous Depot Delivery System For Leuprolide Acetate For The Treatment Of Prostate CancerJournal of Urology, 2002
- FAILURE TO ACHIEVE CASTRATE LEVELS OF TESTOSTERONE DURING LUTEINIZING HORMONE RELEASING HORMONE AGONIST THERAPY: THE CASE FOR MONITORING SERUM TESTOSTERONE AND A TREATMENT DECISION ALGORITHMJournal of Urology, 2000
- The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancerUrology, 1994
- Effect of Orchidectomy on Serum Concentrations of Testosterone and Dihydrotestosterone in Patients with Prostatic CancerScandinavian Journal of Urology and Nephrology, 1992
- Comparison of LHRH Analogue (Zoladex) with Orchiectomy in Patients with Metastatic Prostatic CarcinomaBritish Journal of Urology, 1991
- Leuprolide versus Diethylstilbestrol for Metastatic Prostate CancerNew England Journal of Medicine, 1984